Omaeläinklinikka and Evidensia to form the industry leader in veterinary care in Finland

9 sept 2021

Nordhaven advised Omaeläinklinikka, Korona Invest as well as other owners on the sale of the company to Sweden-rooted IVC Evidensia. IVC Evidensia is Europe’s largest veterinary care provider with operations in 12 countries and its main owner are the funds advised by EQT. The combined Finnish entity operates a network of some 50 clinics, hospitals and out-of-hour centers across the country and has a topline of approx. €90 million. Omaeläinklinikka’s strong brand is planned to be utilized also following the transaction.

Prior to the transaction Omaeläinklinikka was one of the very few larger Nordic platforms available for further veterinary industry consolidation. The company has ca. 450 employees who cater annually some 140,000 physical & digital visits for pets and their owners. The company enjoys very high customer satisfaction.

Once again impressive exit process with very good outcome arranged by Nordhaven for us! The investment story was of high quality, the selection of international buyers was perfect and the sales process well-controlled and competition was kept up until the last day. Working with you is always very easy, fun and we value your independent thinking and working. The sellers are extremely satisfied with the financial outcome.” says Pasi Lehtinen, managing partner at Korona Invest.

We are proud to have again provided significant value-add to our customer by arranging a competitive international auction process. And as many times earlier, the Clairfield International network played an important role in identifying and bringing in potential international buyers. This enabled us to create high competitive tension in the process.” says Timo Lappalainen, partner who was responsible for the project.

Join our newsletter
Subscribe to our newsletter to receive the latest news from Nordhaven Corporate Finance.
  • Helsinki
  • Eteläranta 12
  • +35 8 207 613 910
  • Oslo
  • Hieronymus Heyerdahls gate 1
  • +49 901 38 832
Contact LinkedinPrivacy Policy
Website by Almedialt